Jafron Biomedical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Operating Revenue	2,030	2,670	1,919	2,487	2,671	1,946
Other Revenue	7.33	7.33	3.42	4.54	4.5	4.64
Revenue	2,038	2,677	1,922	2,491	2,675	1,951
Revenue Growth (YoY)	-22.58%	39.27%	-22.84%	-6.88%	37.15%	36.24%
Cost of Revenue	427.5	520.26	390.89	440.36	402.12	288
Gross Profit	1,610	2,157	1,531	2,051	2,273	1,663
Selling, General & Admin	739.61	881.19	787.89	838.78	729.46	587.45
Research & Development	212.41	240.09	245.38	253.91	173.77	80.76
Other Operating Expenses	77.96	37.29	24.61	33.72	39.56	28.24
Operating Expenses	1,019	1,159	1,048	1,124	949.55	697.27
Operating Income	591.55	997.98	482.98	926.66	1,324	965.51
Interest Expense	-56	-63.71	-54.33	-36.04	-8.91	-
Interest & Investment Income	41.51	73.09	87.96	63.79	56.5	44.01
Currency Exchange Gain (Loss)	0.78	0.78	1.22	1.07	-0.81	-0.37
Other Non Operating Income (Expenses)	28.19	-1.73	-2.12	-0.5	-5.34	-2.36
EBT Excluding Unusual Items	606.03	1,006	515.71	954.97	1,365	1,007
Impairment of Goodwill	-5.2	-5.2	-25.61	-6.26	-	-
Gain (Loss) on Sale of Investments	31.61	1.02	-	-0.01	0.01	-
Gain (Loss) on Sale of Assets	-1.58	3.64	6.72	0.86	0.98	-
Asset Writedown	-9.29	-1.04	-1.46	-1.61	-1.15	-0.48
Other Unusual Items	-17.18	2.13	25.66	68.85	42.14	25.64
Pretax Income	604.4	1,007	521.02	1,017	1,407	1,032
Income Tax Expense	127.18	192.78	95.3	135.86	211.38	158.95
Earnings From Continuing Operations	477.22	814.19	425.72	880.95	1,196	873
Minority Interest in Earnings	4.57	6.01	10.77	8.62	0.97	2.24
Net Income	481.79	820.2	436.49	889.56	1,197	875.24
Net Income to Common	481.79	820.2	436.49	889.56	1,197	875.24
Net Income Growth	-40.11%	87.91%	-50.93%	-25.67%	36.74%	53.33%
Shares Outstanding (Basic)	758	781	794	794	803	796
Shares Outstanding (Diluted)	765	781	794	794	803	810
Shares Change (YoY)	-3.68%	-1.57%	-0.08%	-1.12%	-0.89%	2.22%
EPS (Basic)	0.64	1.05	0.55	1.12	1.49	1.10
EPS (Diluted)	0.63	1.05	0.55	1.12	1.49	1.08
EPS Growth	-37.82%	90.91%	-50.89%	-24.83%	37.96%	50.00%
Free Cash Flow	578.69	815.85	669.49	407.91	712	600.37
Free Cash Flow Per Share	0.76	1.04	0.84	0.51	0.89	0.74
Dividend Per Share	0.800	0.800	0.400	0.670	0.900	0.660
Dividend Growth	100.00%	100.00%	-40.30%	-25.56%	36.36%	39.33%
Gross Margin	79.02%	80.57%	79.67%	82.33%	84.97%	85.24%
Operating Margin	29.03%	37.28%	25.12%	37.19%	49.48%	49.49%
Profit Margin	23.64%	30.64%	22.71%	35.70%	44.73%	44.87%
Free Cash Flow Margin	28.40%	30.47%	34.83%	16.37%	26.61%	30.78%
EBITDA	736.68	1,120	573.43	995.72	1,373	1,002
EBITDA Margin	36.15%	41.82%	29.83%	39.97%	51.32%	51.38%
D&A For EBITDA	145.13	121.69	90.44	69.07	49.25	36.73
EBIT	591.55	997.98	482.98	926.66	1,324	965.51
EBIT Margin	29.03%	37.28%	25.12%	37.19%	49.48%	49.49%
Effective Tax Rate	21.04%	19.14%	18.29%	13.36%	15.02%	15.40%
Revenue as Reported	2,038	2,677	1,922	2,491	2,675	1,951

Source: S&P Global Market Intelligence. Standard template. Financial Sources.